Myriad Genetics, Inc. (MYGN) - Medical Equipment - Deals and Alliances Profile

Date: July 21, 2016
Pages: 66
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M359B498AFCEN
Leaflet:

Download PDF Leaflet

Myriad Genetics, Inc. (MYGN) - Medical Equipment - Deals and Alliances Profile
Summary

Myriad Genetics, Inc. (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that are designed to analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient’s likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its own sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics, Inc. (MYGN) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion/divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Myriad Genetics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deal Details
Asset Purchase
Rules-Based Medicine Acquires Intellectual Property Assets From Satoris
Myriad Genetics Acquires Novel Technology From Melanoma Diagnostics
Venture Financing
RainDance Technologies Raises US$20 Million In Series E Financing
Crescendo Bioscience Raises US$28 Million In Series D Financing
Crescendo Bioscience Raises US$56 Million In Series C Financing
Sividon Diagnostics Secures Venture Financing
Crescendo Bioscience Secures US$37.6 Million In Venture Round
Partnerships
Saladax Biomedical Terminates Licensing Agreement With Myriad Genetics
Myriad Genetics Enters Into Licensing Agreement For RAD51C Gene
Myriad Genetics Enters Into Licensing Agreement With Chronix Biomedical
Sividon Diagnostics Enters into Co-Marketing Agreement with Virchow Labs and Ready Ruixin
Myriad Genetics Expands Agreement with AstraZeneca
Myriad Genetics Enters Into Co-Marketing Agreement With Sividon Diagnostics For EndoPredict Test
Myriad Enters Into Research Agreement With Janssen Research & Development
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib
DaVita Enters Into Agreement With Myriad Genetics For Protein Biomarker Discovery
Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits
Acquisition
Myriad Genetics Acquires Sividon Diagnostics
Myriad Genetics Completes Acquisition Of Crescendo Bioscience For US$270 Million
Myriad Genetics Acquires Rules-Based Medicine
Myriad Genetics, Inc. - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Financial Announcements
May 03, 2016: Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results
Feb 02, 2016: Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results
Oct 01, 2015: Myriad Appoints Jan Schluchter as Chief Commercial Officer for Europe
Aug 11, 2015: Myriad Genetics Reports Fiscal Fourth-Quarter and Full Year 2015 Financial Results
May 05, 2015: Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results
Feb 03, 2015: Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results
Corporate Communications
Feb 03, 2015: Myriad Announces Retirement of Peter D. Meldrum, President and CEO
Jan 22, 2015: Myriad Genetics Names Johnathan M. Lancaster as Vice President of Medical Affairs
Legal and Regulatory
Feb 09, 2015: Quest Diagnostics and Myriad Genetics End BRCA Patent Litigation
Jan 26, 2015: Invitae Announces Settlement in Lawsuit with Myriad Genetics
Product News
Mar 18, 2016: Myriad Genetics Presented New Data on myChoice HRD at the Society for Gynecologic Oncology Annual Meeting
Mar 18, 2016: The Myriad myRisk Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer
Mar 15, 2016: Myriad Presents myPlan Lung Cancer test at the 2016 USCAP Annual Meeting
Mar 15, 2016: Myriad Presents Second Pivotal Validation Study for Its myPath Melanoma Test
Mar 08, 2016: Myriad Advances Proprietary myVision Variant Classification Tools to a Broader Range of Cancer Risk Genes
Aug 13, 2015: Myriad Receives Favorable Medicare Ffinal Coverage Decision For Prolaris Test
May 07, 2015: Myriad to Present New Clinical Data on Prolaris at the AUA 2015 Annual Meeting
Mar 20, 2015: Myriad Announces Prolaris Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting
Mar 04, 2015: Myriad Publishes myPath Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology
Jan 08, 2015: Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors
Product Approvals
Jan 08, 2015: Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors
Other Significant Developments
May 18, 2016: Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Myriad Genetics, Inc., Medical Equipment, Key Facts, 2015
Myriad Genetics, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016
Myriad Genetics, Inc., Deals By Market, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016
Rules-Based Medicine Acquires Intellectual Property Assets From Satoris
Myriad Genetics Acquires Novel Technology From Melanoma Diagnostics
RainDance Technologies Raises US$20 Million In Series E Financing
Crescendo Bioscience Raises US$28 Million In Series D Financing
Crescendo Bioscience Raises US$56 Million In Series C Financing
Sividon Diagnostics Secures Venture Financing
Crescendo Bioscience Secures US$37.6 Million In Venture Round
Saladax Biomedical Terminates Licensing Agreement With Myriad Genetics
Myriad Genetics Enters Into Licensing Agreement For RAD51C Gene
Myriad Genetics Enters Into Licensing Agreement With Chronix Biomedical
Sividon Diagnostics Enters into Co-Marketing Agreement with Virchow Labs and Ready Ruixin
Myriad Genetics Expands Agreement with AstraZeneca
Myriad Genetics Enters Into Co-Marketing Agreement With Sividon Diagnostics For EndoPredict Test
Myriad Enters Into Research Agreement With Janssen Research & Development
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib
DaVita Enters Into Agreement With Myriad Genetics For Protein Biomarker Discovery
Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits
Myriad Genetics Acquires Sividon Diagnostics
Myriad Genetics Completes Acquisition Of Crescendo Bioscience For US$270 Million
Myriad Genetics Acquires Rules-Based Medicine
Myriad Genetics, Inc., Key Competitors
Myriad Genetics, Inc., Key Employees
Myriad Genetics, Inc., Subsidiaries

LIST OF FIGURES

Myriad Genetics, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016
Myriad Genetics, Inc., Medical Equipment, Deals by Market, 2010 to YTD 2016
Skip to top


Ask Your Question

Myriad Genetics, Inc. (MYGN) - Medical Equipment - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: